Serotonergic agents and the irritable bowel syndrome: what goes wrong?

Current Opinion in Pharmacology

Volumn 8, Issue 6, 2008, Pages 709-714

  Spiller, Robin ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; CILANSETRON; MESSENGER RNA; ONDANSETRON; PLACEBO; PRUCALOPRIDE; RAMOSETRON; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN AGONIST; SEROTONIN TRANSPORTER; TEGASEROD; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 2;

ABDOMINAL PAIN; ANTINOCICEPTION; CLINICAL TRIAL; COLON MOTILITY; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG WITHDRAWAL; ENTEROENDOCRINE CELL; GENETIC POLYMORPHISM; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; RISK BENEFIT ANALYSIS; SEROTONIN RELEASE; THROMBOSIS;

ANIMALS; BIBLIOMETRICS; HUMANS; IRRITABLE BOWEL SYNDROME; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN AGENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 55649112489     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.07.003     Document Type: Review

References (56)

1. Wheatcroft J., Wakelin D., Smith A., Mahoney C.R., Mawe G., and Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 17 (2005) 863-870
2. Wang S.H., Dong L., Luo J.Y., Gong J., Li L., Lu X.L., and Han S.P. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol 13 (2007) 6041-6047
3. Dunlop S.P., Jenkins D., Neal K.R., and Spiller R.C. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125 (2003) 1651-1659. A study of post infective IBS demonstrating increase in PPP-5HT postprandially with depressed levels in constipated IBS compared with controls.
4. Dunlop S.P., Coleman N.S., Blackshaw E., Perkins A.C., Singh G., Marsden C.A., and Spiller R.C. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 3 (2005) 349-357
5. Liu Q., Yang Q., Sun W., Vogel P., Heydorn W., Yu X.Q., Hu Z., Yu W., Jonas B., Pineda R., et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 325 (2008) 47-55
6. Braun T., Voland P., Kunz L., Prinz C., and Gratzl M. Enterochromaffin cells of the human gut: sensors for spices and odorants. Gastroenterology 132 (2007) 1890-1901. Study of intracellular calcium and serotonin secretory response of cultured cells derived from intestinal carcinoid tumour to a range of herbal products including bitter tastants. Also demonstrated mRNA for specific taste receptors.
7. Fukumoto S., Tatewaki M., Yamada T., Fujimiya M., Mantyh C., Voss M., Eubanks S., Harris M., Pappas T.N., and Takahashi T. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 284 (2003) R1269-R1276
8. Gill R.K., Pant N., Saksena S., Singla A., Nazir T.M., Vohwinkel L., Turner J.R., Goldstein J., Alrefai W.A., and Dudeja P.K. Function, expression, and characterization of the serotonin transporter in the native human intestine. Am J Physiol Gastrointest Liver Physiol 294 (2008) G254-G262. Systematic investigation of SERT expression and function throughout the human intestine showing clearly the very low levels found in the colon with much higher levels in the duodenum and ileum indicating important regional differences in serotonin handling.
9. Atkinson W., Lockhart S., Whorwell P.J., Keevil B., and Houghton L.A. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 130 (2006) 34-43. A large study of 29 C-IBS, 55 D-IBS and 35 healthy volunteers showing that PPP-5HT levels were elevated in D-IBS both fasting and fed, while C-IBS patients failed to show a meal related increase.
10. Houghton L.A., Atkinson W., Lockhart S., Fell C., Whorwell P.J., and Keevil B. Sigmoid-colonic motility in health and irritable bowel syndrome: a role for 5-hydroxytryptamine. Neurogastroenterol Motil 19 (2007) 724-731
11. Zuo X.L., Li Y.Q., Shi L., Lv G.P., Kuang R.G., Lu X.F., Li J.M., and Desmond P.V. Visceral hypersensitivity following cold water intake in subjects with irritable bowel syndrome. J Gastroenterol 41 (2006) 311-317
12. Zuo X.L., Li Y.Q., Yang X.Z., Guo M., Guo Y.T., Lu X.F., Li J.M., and Desmond P.V. Plasma and gastric mucosal 5-hydroxytryptamine concentrations following cold water intake in patients with diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol 22 (2007) 2330-2337
13. Meier Y., Eloranta J.J., Darimont J., Ismair M.G., Hiller C., Fried M., Kullak-Ublick G.A., and Vavricka S.R. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos 35 (2007) 590-594
14. Coates M.D., Mahoney C.R., Linden D.R., Sampson J.E., Chen J., Blaszyk H., Crowell M.D., Sharkey K.A., Gershon M.D., Mawe G.M., and Moses P.L. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126 (2004) 1657-1664
15. Camilleri M., Andrews C.N., Bharucha A.E., Carlson P.J., Ferber I., Stephens D., Smyrk T.C., Urrutia R., Aerssens J., Thielemans L., et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 132 (2007) 17-25
16. Kerckhoffs A.P., Ter Linde J.J., Akkermans L.M., and Samsom M. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil 20 (2008) 900-907
17. Yeo A., Boyd P., Lumsden S., Saunders T., Handley A., Stubbins M., Knaggs A., Asquith S., Taylor I., Bahari B., et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 53 (2004) 1452-1458
18. Park J.M., Choi M.G., Park J.A., Oh J.H., Cho Y.K., Lee I.S., Kim S.W., Choi K.Y., and Chung I.S. Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil 18 (2006) 995-1000
19. Van Kerkhoven L.A., Laheij R.J., and Jansen J.B. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 26 (2007) 979-986. Meta-analysis showing no consistent association of SERT promoter polymorphism with IBS. Important since it shows striking differences in the polymorphism frequencies in Asians versus Caucasians, which suggests that caution is necessary when comparing studies in different racial groups
20. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., and Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996) 1527-1531. Seminal paper showing that possession of the short form of the 5-HTTLPR polymorphism is associated with a strong correlation between adverse life events and the development of depression, which is not seen in those lacking this gene. Points the way for future studies, which should examine the interaction between genes and environmental triggers to disease.
21. You J.S., Hu S.Y., Chen B., and Zhang H.G. Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. Psychiatr Genet 15 (2005) 7-11
22. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., and Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301 (2003) 386-389
23. Lee H.J., Lee M.S., Kang R.H., Kim H., Kim S.D., Kee B.S., Kim Y.H., Kim Y.K., Kim J.B., Yeon B.K., et al. Influence of the serotonin transporter promoter gene polymorphism on susceptibility to posttraumatic stress disorder. Depress Anxiety 21 (2005) 135-139
24. 3 antagonist, Alosetron.
25. 3 antagonists.
26. Camilleri M., Atanasova E., Carlson P.J., Ahmad U., Kim H.J., Viramontes B.E., McKinzie S., and Urrutia R. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123 (2002) 425-432
27. 3 antagonists. This also documents the 2 in 1000 incidences of ischaemic colitis.
28. Chang L., Ameen V.Z., Dukes G.E., McSorley D.J., Carter E.G., and Mayer E.A. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 100 (2005) 115-123
29. Gallo-Torres H., Brinker A., and Avigan M. Alosetron: ischemic colitis and serious complications of constipation. Am J Gastroenterol 101 (2006) 1080-1083
30. Chang L., Chey W.D., Harris L., Olden K., Surawicz C., and Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 101 (2006) 1069-1079
31. Gunput M.D. Review article: clinical pharmacology of alosetron. Aliment Pharmacol Ther 13 Suppl. 2 (1999) 70-76
32. Fu L.W., O'Neill C.A., and Longhurst J.C. Increased histamine and 5-HT in portal vein plasma and mesenteric lymph during brief ischemia and reperfusion. Am J Physiol 273 (1997) H1135-H1141
33. Fu L.W., and Longhurst J.C. Role of 5-HT3 receptors in activation of abdominal sympathetic C fibre afferents during ischaemia in cats. J Physiol 509 Pt 3 (1998) 729-740
34. Grundy D., McLean P., and Stead R. Impact of 5-HT3 receptor blockade on colonic haemodynamic responses to ischaemia and reperfusion in the rat. Neurogastroenterol Motil 19 (2007) 607-616. A detailed study of the effect of Alosetron on colonic haemodynamic demonstrating no impact on either baseline haemodynamic or post occlusive reactive hyperaemia.
35. Lewis S.J., Heaton K.W., Oakey R.E., and McGarrigle H.H. Lower serum oestrogen concentrations associated with faster intestinal transit. Br J Cancer 76 (1997) 395-400
36. 3 receptors in the gut.
37. Tsukamoto K., Ariga H., Mantyh C., Pappas T.N., Yanagi H., Yamamura T., and Takahashi T. Luminally released serotonin stimulates colonic motility and accelerates colonic transit in rats. Am J Physiol Regul Integr Comp Physiol 293 (2007) R64-R69
38. Mori N., Suzuki R., Furuno T., McKay D.M., Wada M., Teshima R., Bienenstock J., and Nakanishi M. Nerve-mast cell (RBL) interaction: RBL membrane ruffling occurs at the contact site with an activated neurite. Am J Physiol Cell Physiol 283 (2002) C1738-C1744
39. Bradesi S., Lao L., McLean P.G., Winchester W.J., Lee K., Hicks G.A., and Mayer E.A. Dual role of 5-HT3 receptors in a rat model of delayed stress-induced visceral hyperalgesia. Pain 130 (2007) 56-65
40. Hirata T., Keto Y., Nakata M., Takeuchi A., Funatsu T., Akuzawa S., Sasamata M., and Miyata K. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil 20 (2008) 557-565
41. Funatsu T., Takeuchi A., Hirata T., Keto Y., Akuzawa S., and Sasamata M. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. Eur J Pharmacol 573 (2007) 190-195
42. Mayer E.A., Berman S., Derbyshire S.W., Suyenobu B., Chang L., Fitzgerald L., Mandelkern M., Hamm L., Vogt B., and Naliboff B.D. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 16 (2002) 1357-1366
43. De Maeyer J.H., Lefebvre R.A., and Schuurkes J.A. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 20 (2008) 99-112
44. Evans B.W., Clark W.K., Moore D.J., and Whorwell P.J. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev (2004) CD003960
45. Bouras E.P., Camilleri M., Burton D.D., Thomforde G., McKinzie S., and Zinsmeister A.R. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 120 (2001) 354-360
46. Sloots C.E., Poen A.C., Kerstens R., Stevens M., De P.M., Van Oene J.C., Meuwissen S.G., and Felt-Bersma R.J. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 16 (2002) 759-767
47. Krogh K., Jensen M.B., Gandrup P., Laurberg S., Nilsson J., Kerstens R., and De P.M. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 37 (2002) 431-436
48. Coremans G., Kerstens R., De P.M., and Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 67 (2003) 82-89
49. Camilleri M., Kerstens R., Rykx A., and Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358 (2008) 2344-2354
50. Morganroth J., Ruegg P.C., Dunger-Baldauf C., ppel-Dingemanse S., Bliesath H., and Lefkowitz M. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 97 (2002) 2321-2327
51. Pasricha P.J. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 132 (2007) 2287-2290
52. Harish K., Hazeena K., Thomas V., Kumar S., Jose T., and Narayanan P. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. J Gastroenterol Hepatol 22 (2007) 1183-1189
53. Prather C.M., Camilleri M., Zinsmeister A.R., McKinzie S., and Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 118 (2000) 463-468
54. Liang L.X., Zhang Q., Qian W., and Hou X.H. Antinociceptive property of tegaserod in a rat model of chronic visceral hypersensitivity. Chin J Dig Dis 6 (2005) 21-25
55. Sabate J.M., Bouhassira D., Poupardin C., Wagner A., Loria Y., and Coffin B. Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. Neurogastroenterol Motil 20 (2008) 134-141
56. Greenwood-Van Meerveld B., Venkova K., Hicks G., Dennis E., and Crowell M.D. Activation of peripheral 5-HT receptors attenuates colonic sensitivity to intraluminal distension. Neurogastroenterol Motil 18 (2006) 76-86